NCT06786234RecruitingPhase 2
A Phase 2 Study to Assess STP938 (Dencatistat) as a Monotherapy in Adults With High Risk Essential Thrombocythaemia - The VECTRA Trial
An Open-Label, Phase 2 Study to Evaluate Safety, Tolerability & Preliminary Activity of the CTPS1 Inhibitor STP938 in Adult Subjects With High Risk Essential Thrombocythaemia Who Are Resistant to or Intolerant of Hydroxycarbamide Therapy
Source: ClinicalTrials.gov · Last updated 16 Jun 2026
Brief summary (registry, in English)
The goal of this clinical trial is to learn if the drug STP938 works to treat adults with high risk essential thrombocythaemia (ET) who are resistant to, or intolerant of, hydroxycarbamide (also known as hydroxyurea) therapy. The trial will also learn about the safety of STP938. The main questions the trial aims to answer are: * Does STP938 control platelet counts * Does STP938 control platelet counts without inducing unwanted side effects Participants will: * Take STP938 every day for up to 12 months. * Visit the clinic once every week for the first month, then every 2 weeks for checkups and tests. * Complete a questionnaire about symptoms once a month.
- Status (registry)
- Recruiting
- Phase (registry)
- Phase 2
- Study type
- Interventional
- Enrollment
- 50 (estimated)
- First submitted
- 8 Jan 2025
- Start date
- 18 Jun 2025
- Primary completion date
- 30 Jun 2028
- Lead sponsor
- Step Pharma, SAS
- Diseases
- Myeloproliferative neoplasms
- NCT number
- NCT06786234
What you commit to
- Study type: Interventional · Phase 2
- Planned participants: 50
- From 18 Jun 2025 to the primary completion date, 30 Jun 2028
- 14 sites in 2 countries
- Visits and tests: ask the trial team, the registry does not list them
Built from the registry fields of ClinicalTrials.gov. It describes the study, not your situation.
Who cannot take part
Copied verbatim from ClinicalTrials.gov and grouped by topic. Only the trial team decides who can take part.
Prior treatment
- Subjects currently or recently receiving cytoreductive therapy for the treatment of essential thrombocythaemia (wash out periods apply).
- Subjects who have received any investigational agents for the treatment of essential thrombocythaemia within 4 weeks before enrolment or less than 5 half-lives since completion of prior therapy, whichever is shorter.
- Previous splenectomy.
Other illness
- Known malabsorption syndrome or other condition that may impair absorption of study medication (e.g. gastrectomy).
- Any uncontrolled intercurrent illness.
- Immunocompromised subjects with increased risk of opportunistic infections.
- Known active or chronic hepatitis B or active hepatitis C virus (HCV) infection.
- Known hypersensitivity to any of the excipients used in the formulation of the study drug.
Lab values
- Corrected QT interval \>470 msec based on averaged triplicate electrocardiogram (ECG) readings at the Screening Visit using the QT interval corrected for heart rate using Fridericia's method (QTcF).
Age
- Pregnant females, breastfeeding females, and women of child bearing age or males not willing to comply with contraceptive requirements.
Other
- Proven or suspected transformation to polycythaemia vera, myelofibrosis, myelodysplasia, acute myeloid leukaemia or another myeloid neoplasm.
Who the study is looking for
- Adults aged 18 years or older
- A confirmed diagnosis of ET according to World Health Organisation (WHO) or British Society for Haematology (BSH) criteria.
- Meeting criteria for high risk ET.
- Raised platelet count (\>600 x109/L) requiring cytoreductive therapy.
- Neutrophil count \>1.0 x109/L.
- Either intolerant of or resistant to hydroxycarbamide having met any one of the criteria at any point in their disease whilst receiving hydroxycarbamide.
- Adequate hepatic function.
- Adequate blood coagulation parameters.
- Eastern Cooperative Oncology Group (ECOG) status of 0-2.
Age in the registry: 18 years to - · Sex: All · Does not accept healthy volunteers
Sites (14)
Sites in registry order. Pick your city on the disease page to sort them by distance.
| Site | City | Country | Site status |
|---|---|---|---|
| Chu Brest Coordinator of this site? Confirm its status | Brest | France | Recruiting |
| Institut Paoli-Calmettes Coordinator of this site? Confirm its status | Marseille | France | Recruiting |
| CHU Nantes Coordinator of this site? Confirm its status | Nantes | France | Recruiting |
| CHU Nice Coordinator of this site? Confirm its status | Nice | France | Recruiting |
| CHU Nîmes Coordinator of this site? Confirm its status | Nîmes | France | Recruiting |
| Hopital Saint Louis Coordinator of this site? Confirm its status | Paris | France | Recruiting |
| Hôpital de la Milétrie, CHU Coordinator of this site? Confirm its status | Poitiers | France | Not yet recruiting |
| Gustave Roussy Coordinator of this site? Confirm its status | Villejuif | France | Recruiting |
| University Hospital of Wales Coordinator of this site? Confirm its status | Cardiff | United Kingdom | Recruiting |
| Imperial College London - Hammersmith Hospital Coordinator of this site? Confirm its status | London | United Kingdom | Recruiting |
| Sarah Cannon Research Institute Coordinator of this site? Confirm its status | London | United Kingdom | Recruiting |
| Cancer and Haematology Centre, Churchill Hospital Coordinator of this site? Confirm its status | Oxford | United Kingdom | Recruiting |
| Royal Hallamshire Hospital Coordinator of this site? Confirm its status | Sheffield | United Kingdom | Recruiting |
| University of Southampton Hospital Coordinator of this site? Confirm its status | Southampton | United Kingdom | Recruiting |
This page is information, not medical advice. Discuss any trial with your doctor.